Putney Named to 2013 Inc. 5000 List
Putney Named to 2013 Inc. 5000 List
Monday, Aug. 26, 2013
FOR IMMEDIATE RELEASE
PORTLAND, Maine — Putney, Inc., a rapidly growing pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has been named to the 2013 Inc. 5000 list, Inc. magazine’s annual ranking of the fastest growing private companies in America for the second time. Putney earned the position of 2,043 in recognition of its 182 percent revenue growth between 2009 and 2012.
Eric Schurenberg, editor in chief of Inc. magazine, said, “The Inc. 5000 was harder to get into this year than ever in its history,” in a press release.
Jean Hoffman, president and CEO of Putney, says she expects Putney’s growth to continue, fueled by two first to market generic product launches in 2013 and the company’s large pipeline of drugs for dogs and cats.
Earlier this year, Putney launched Putney Enrofloxacin Flavored Tablets (the first and only FDA approved veterinary generic of Baytril® Taste Tabs®) and Putney Cefpodoxime Proxetil tablets (the first and only FDA approved veterinary generic of Simplicef®).
Hoffman says there are two contributions to Putney’s growth: market penetration and market expansion. “Putney has not only taken share from branded pet pharmaceutical companies, we have grown the pie.
Many pets go untreated or are prescribed lower cost human generics that are not approved for use in pets because of the high cost of pet medicines. Putney’s high quality, affordable generics mean that more pets receive the veterinarian’s first choice of treatment. The success of our initial product launches gives us confidence in our business model and value proposition for our veterinarian customers, for pet owners, and for our distribution partners,” says Hoffman.
Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney’s reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. Putney’s ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more at www.putneyvet.com.